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ABSTRACT
The research focus of this thesis is polycystic ovary syndrome (PCOS), the most com-
mon endocrine disorder among women of reproductive age, associated with reproduc-
tive, cardio-metabolic, and mental health complications. Despite the high prevalence, 
little is known about the etiology of the syndrome. The scope of the current thesis was 
to investigate aspects of the developmental origins of the syndrome, with focus on 
the impact of adverse environmental factors during pregnancy on PCOS-associated 
features in the offspring. To reach these aims we employed three mouse model of 
PCOS and data from a Swedish national register-based cohort study.
The thesis is divided into two parts. Part 1 investigates the effects of maternal andro-
gen excess and maternal obesity on the mental health of adult male and female off-
spring. Study I demonstrated that maternal androgen exposure increases anxiety-like 
behavior in the first generation of female mouse offspring, but not male offspring, 
while maternal obesity affects male offspring behavior, but not female offspring. 
This sexually dimorphic response to the two prominent environmental stimuli was 
further supported by sex-specific changes in gene expression within the amygdala 
and hypothalamus. Study II provided evidence that daughters of women with PCOS 
are at increased risk to be diagnosed with anxiety disorders, but not the sons, using a 
Swedish national register-based cohort study. It further showed that maternal androgen 
exposure can lead to transgenerational transmission of anxiety-like behavior in the 
third generation of female mice, but not the male offspring, without major impact of 
maternal obesity. Finally, the male germline (first generation of male offspring with 
no change in behavior) did also transgenerationally transmit an anxiety-like behavior 
to the third generation of male offspring. 
Part 2 investigates the effects of an adverse maternal and/or postnatal environment 
on the cardiovascular and metabolic health of females, using mouse models of PCOS. 
Study III revealed that maternal androgen excess leads to cardiac hypertrophy in 
adult female offspring, accompanied by gene expression changes in the left ven-
tricle, without the presence of metabolic dysfunction. It was further shown that this 
adverse cardiac phenotype is the result of an early cardiac reprogramming. In addi-
tion, cardiovascular assessment of a mouse model of PCOS with continuous exposure 
to androgens from prepuberty to adulthood, demonstrated cardiac hypertrophy and 
increased vasocontractile responses, while simultaneous administration of the anti-
androgen flutamide could only partially prevent the observed phenotype. Finally, in 
study IV, developmental, reproductive and metabolic complications were revealed in 
a transgenic mouse model of PCOS that overexpresses ovarian nerve growth  factor. 
Ovarian excess of nerve growth factor led to developmental defects in the female 
fetus, including growth restriction, reduction of germ cell number and delayed pri-
mary oocyte maturation. In addition, the adult transgenic female mice displayed dis-
rupted estrous cyclicity and ovarian expression changes of steroidogenic genes and 
epi genetic markers. Lastly, these mice developed metabolic complications, as shown 
by impaired glucose metabolism, aberrant adipose tissue function, and liver steatosis. 
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11 INTRODUCTION
1.1 Polycystic ovary syndrome
1.1.1 Definition
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among 
women of reproductive age, which is characterized by clinical or biochemical 
hyperandrogenism (hirsutism, acne/excess of circulating androgens, respectively), 
oligoovulation or anovulation, and polycystic ovarian morphology (1, 2). PCOS 
manifests with a heterogeneous phenotype, it is the main cause of anovulatory 
infertility, and it is linked to metabolic, cardiovascular and mental complications 
in the affected women (3). 
PCOS was first described by Stein and Leventhal in 1935. The investigators char-
acterized a group of seven women that shared symptoms of menstrual irregularities, 
hirsutism, and enlarged ovaries with many small follicles. Treatment with bilateral 
ovarian wedge resection resulted in menstrual improvements and five of them 
became pregnant after the treatment. Of the two remaining subjects, one discon-
tinued the follow-up and the other faced concomitant male factor  infertility (4-6). 
Since then, many researchers have attempted to further characterize the  phenotype 
of the syndrome, to elucidate its origins, and to apply various treatments in order 
to alleviate the symptoms in the affected women.
1.1.2 Diagnostic Criteria and Prevalence
Diagnostic criteria
It was more than five decades after the initial description of the syndrome, that 
the first formal diagnostic criteria were proposed at a conference on PCOS spon-
sored by the National Institutes of Health (NIH) in 1990. These criteria, which 
are known as the NIH criteria, require the presence of hyperandrogenism (clini-
cal or biochemical) and ovulatory dysfunction for the diagnosis of the syndrome, 
excluding the presence of other disorders that lead to similar features. While the 
NIH criteria have been widely accepted, increasing research in the PCOS field 
the upcoming years, led to the refinement of the NIH criteria. In 2003, a group of 
experts at a conference that took place in Rotterdam, in the Netherlands, revisited 
the NIH criteria and decided to include features of polycystic ovarian morphol-
ogy in the diagnostic criteria (2). The Rotterdam consensus is widely endorsed for 
the diagnosis of the syndrome and it is currently in clinical use. According to the 
Rotterdam criteria, at least two of the following features should be present for the 
diagnosis of PCOS: 1) clinical or biochemical hyperandrogenism (hirsutism/excess 
levels of androgens, respectively); 2) oligo-anovulation (menstrual dysfunction); 
and 3) polycystic ovaries (PCO) (excessive number of preantral follicles in the ova-
ries and/or enlarged ovaries), with the exclusion of other disorders. The use of the 
2Rotterdam criteria gives rise to four PCOS phenotypes, which may differ in severity, 
depending on the presence or not of hyperandrogenism. Of note, hyperandrogenism 
is evidenced to coincide with both the reproductive and metabolic abnormalities of 
the syndrome (7). To cope with this phenotypic heterogeneity, the Androgen Excess 
and PCOS (AE-PCOS) society in 2006 suggested that hyper androgenism should be 
a prerequisite for the diagnosis of the syndrome, followed by either ovulatory dys-
function or polycystic ovarian morphologic features (8). The three different sets of 
diagnostic criteria of PCOS are summarized in Table 1, and the PCOS phenotypes 
that arise using the Rotterdam criteria are presented in table 2.
Table 1. Diagnostic criteria of PCOS (Adapted from (9))
Features NIH 1990 Rotterdam 2003 AE-PCOS Society 2006
Hyperandrogenism Hyperandrogenism 
required
Any two of the 
three features 
 (hyper androgenism, 
ovulatory  dysfunction, 
polycystic  ovarian 
morphologic  features) 
required
Hyperandrogenism 
required
Oligo-ovulation 
or anovulation
Ovulatory 
 dysfunction  
required
Any two of the 
three features 
 (hyperandrogenism, 
ovulatory  dysfunction, 
polycystic  ovarian 
morphologic  features) 
required
Either ovulatory 
 dysfunction or  polycystic 
ovarian morphologic 
 features required
Polycystic  ovarian 
morphologic 
features
Not applicable Any two of the 
three features 
 (hyperandrogenism, 
ovulatory dysfunction, 
polycystic ovarian 
morphologic features) 
required
Either ovulatory 
 dysfunction or  polycystic 
ovarian morphologic 
 features required
Table 2. Four phenotypes of PCOS using the Rotterdam 2003 criteria
Phenotypes Hyperandrogenism Oligo/anovulation Polycystic ovaries
Phenotype 1  
(“classic” PCOS)
√ √ √
Phenotype 2  
(NIH criteria)
√ √ ×
Phenotype 3  
(ovulatory PCOS)
√ × √
Phenotype 4  
(non-hyperandrogenic PCOS)
× √ √
3Prevalence
PCOS is a prevalent disorder that affects women of reproductive age across all 
races and ethnicities. Due to the different diagnostic criteria used and the high 
number of undiagnosed cases, the prevalence of the syndrome varies. Based on 
the results of a recent systematic review and meta-analysis, the prevalence reaches 
6% (5-8%) worldwide using the stringent NIH criteria, while it is 10% following 
the Rotterdam 2003 (8-13%) and the AE-PCOS society 2006 (7-13%) criteria 
(10). There is no adequate literature to support geographical and racial differences 
in the prevalence of the syndrome (11). Yet, a small-scale study found that the 
prevalence of PCOS in adult normal weight Indigenous Australian women was 
15% and as high as 30% when the body mass index was above 30 kg/m2, using 
the NIH criteria (12). Moreover, a study in severely obese women (BMI>35 kg/m2) 
found that the prevalence of PCOS was 25,6% (13). 
1.1.3 Pathophysiology
The pathophysiology of PCOS is rather complex and our knowledge is incom-
plete partly due to the diverse phenotypic profiles of women with the syndrome. 
The most common defect in PCOS is ovarian hyperandrogenism, which is pre-
sent in more than 85% of women with PCOS and originates from an unexplained 
 steroidogenic hyperactivity and leads to increased ovarian theca cell production and 
secretion of androgens, and ovulatory dysfunction (14). Other possible components 
that underlie the pathogenesis of the syndrome and lead to the clinical features of 
PCOS are depicted in Figure 1. Almost 50% of women with PCOS display elevated 
levels of luteinizing hormone (LH) along with increased LH pulse amplitude (15). 
LH controls the expression of gonadal steroidogenic enzymes and the secretion of 
sex hormones. An increased pulsatile release of gonadotropin-releasing hormone 
from the hypothalamus may lead to increased pulse frequency of the luteinizing 
hormone by the pituitary gland at the expense of follicle-stimulating hormone. 
This neuroendocrine defect leads to increased ovarian theca cell production and 
secretion of androgens and ovulatory dysfunction (16). Moreover, insulin resist-
ance and hyperinsulinemia are present in about 30% of women with PCOS (17). 
The origins of insulin resistance in PCOS are of intrinsic character in most cases, 
while it can be a consequence of obesity in some cases. Insulin stimulates andro-
gen production by directly stimulating the theca cells, and hyperinsulinemia in 
PCOS further contributes to increase of ovarian androgen production (18-20). In 
addition, hyperinsulinemia inhibits the hepatic synthesis and secretion of the sex 
hormone transporter, sex hormone binding globulin (21), which further contrib-
utes to hyperandrogenemia (22). Sympathetic nerve activity is elevated in women 
with PCOS and the common features of the syndrome, such as hyperandrogenism, 
insulin resistance and obesity contribute to increased sympathetic nerve activity in 
4these women (23, 24). The role of sympathetic nerve activity in the pathophysiol-
ogy of PCOS will be discussed in more detail in the part II of this thesis. Finally, 
the interplay among the for mentioned mechanisms constitutes a vicious circle 
and leads to long-term health complications in the affected women (Figure 1). 
Figure 1. Pathophysiology of PCOS.
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1.1.4 Etiology
A large piece of evidence indicates that genetic, intrauterine and postnatal environ-
mental factors are implicated in the etiology of the disorder (25). Starting with 
the genetic factors, familial and twin studies have revealed that the heritability 
of PCOS reaches the 70% and follows an autosomal dominant fashion (26-29). 
Despite the high heritable character of the syndrome, studies aiming to discover 
target candidate genes that cause PCOS have been hampered by the phenotypic 
heterogeneity of the syndrome itself and the complex variety of identified genes. 
Moreover, genome-wide association studies (GWAS) have attempted to identify 
loci that could be implicated in the etiology of the syndrome, but the PCOS loci that 
have been identified so far account for less than 10% of the heritability (30). Some 
candidate genes that have been associated with PCOS in Chinese and European 
populations by GWAS are the following: LHCGR, FSHR, THADA, DENND1A, 
FSHB, RAB5B/SUOX, HMGA2, TOX3 and INSR. These genes are involved in 
hormonal regulation, insulin signaling and organ growth (29). 
5The intrauterine environment is an important environmental factor that has been 
implicated in PCOS etiology. Pregnant women with PCOS have elevated levels 
of androgens during the second and third trimester, which could pose the devel-
oping fetus at risk for exposure to excess androgens (31-33). Studies in animal 
models of PCOS, including non-human primates, sheep and rodents have shed 
light into the effects of in utero virilization in the developing embryo, and accu-
mulating data indicate that gestational androgen excess can lead to PCOS traits 
in the adult offspring (34). Obesity is another crucial environmental factor that 
is tightly linked to PCOS. It is highly debated whether obesity per se can lead to 
PCOS, yet it is believed to lead to symptom manifestation in genetically suscep-
tible individuals (14). 
All in all, there is need for a better understanding of the genetic, epigenetic and 
environmental factors as well as the interaction among them, in order to better 
understand the etiology of PCOS. 
1.2 Animal models of PCOS
Over the last 50 years, animal models of experimentally induced PCOS have been 
developed to examine the etiology of PCOS and facilitate the understanding of 
the complex aspects of the syndrome (34, 35). Despite the lack of an established 
animal model that mirrors all symptoms of the syndrome, various animal models 
exposed to different interventions develop a PCOS-like phenotype resembling 
reproductive, metabolic and behavioral traits of the syndrome. Starting with the in 
utero programming of the syndrome, prenatally androgenized non-human primates, 
sheep and rodents during early or late gestation have given substantial evidence 
that PCOS may originate from an adverse intrauterine environment with androgen 
excess. Prenatally androgenized rhesus monkeys and sheep are the best models 
to study PCOS as they closely mimic the human traits of the syndrome, including 
hyperandrogenism, oligo- or anovulation, and polyfollicular ovaries. Moreover, 
they develop many neuroendocrine, metabolic and behavioral abnormalities that 
are present in women with PCOS (36, 37). However, the use of these animals is 
expensive and requires a long experimental time due to their long reproductive 
cycle. Therefore, many researchers have focused their research on prenatal andro-
genized rodent models, since they have a short estrous cycle of 4-5 days and a 
short reproductive cycle. These studies have provided us with important insight 
into the possible mechanisms of action, yet the androgenized rodent offspring 
resemble partially the human PCOS phenotype (38-48). Although they display 
irregular cyclicity, signs of metabolic, neuroendocrine and behavioral complica-
tions, the results concerning the hyperandrogenism and the ovarian morphology 
are conflicting. 
6Moreover, animal models of neonatal and prepubertal androgen exposure have been 
generated to study the role of hyperandrogenemia in the development of PCOS-
like features (49-56). Studies in monkeys exposed to slightly elevated testosterone 
from prepuberty showed modest neuroendocrine defects, with no major changes 
in metabolic and ovarian features (50, 51). On the other hand, prepubertal expo-
sure of mice to androgens have shown robust ovarian and metabolic changes (53). 
Interventions including estrogen, letrozole, antiprogesterone agent administration 
during critical developmental stages as well as constant light exposure, D-galactose 
and valproic acid are some additional examples of studies in rodents that tried 
to resemble the human PCOS (57-61). Finally, genetic mouse models have been 
developed to assess the role of specific genes in the pathophysiology of the syn-
drome. These models include the 17NF transgenic mice that overexpress nerve 
growth factor selectively in the theca-interstitial cells (62), and will be extensively 
discussed in the part II of this thesis book, mice with targeted overexpression of 
luteinizing hormone (63), human chorionic gonadotropin (64), plasminogen activa-
tor inhibitor-1 (65), prohibitin (66), and mice lacking leptin and insulin receptors 
in pro-opiomelanocortin neurons (67). 
The animal models have tremendously helped us to study and understand some 
aspects of the pathophysiology of the syndrome; yet, it is questionable to which 
extent we can translate these findings into the human condition. Taking into 
consideration the lack of an ideal animal model to study PCOS, it is crucial for 
the researchers in the field to choose the most appropriate model for the study of 
specific aspects of PCOS.
71.3 This thesis
The overall scope of the current thesis is to provide novel insight into the develop-
mental origins of PCOS, focusing on the impact of an adverse intrauterine environ-
ment on PCOS-related outcomes in the offspring. 
The thesis consists of two parts, Part 1 and Part 2. Part 1 describes the studies I 
and II and examines how adverse environmental factors, including maternal obe-
sity and maternal androgen excess, impact on behavioral health in the offspring 
and whether changes in behavior can be transmitted transgenerationally, using the 
prenatally androgenized mouse model. Moreover, it examines if PCOS in mothers 
increases the risk of anxiety disorders in the daughters and sons. Part 2 describes 
studies III and IV and examines 1) the impact of maternal androgen excess on 
cardio-metabolic outcomes in the offspring, along with the effects of postnatal 
androgen excess on the cardiovascular system (study III), and 2) the impact of ovar-
ian sympathetic hyperactivity on the development of PCOS-like features, including 
developmental, reproductive and metabolic complications (study IV). Studies III 
and IV employ three different mouse models of PCOS to answer these questions. 
82 PART 1: PCOS AND MENTAL HEALTH 
DISORDERS
2.1 Background 
Mental health disorders comprise a wide range of mental complications, which 
manifest with different symptoms. General features are abnormal thoughts, emo-
tions and behavior. Mental health disorders are among the leading causes of ill-
health, affecting about 25% of the population worldwide (68). Anxiety disorders 
are the most common mental health disorders, they are characterized by excessive 
fear or anxiety, and affect women more than men (69, 70). 
Women with PCOS are at increased risk of developing mental disorders (71-76). 
A recent review showed that 36.6% of women with PCOS have anxiety symp-
toms compared to 8.5% of women without the syndrome (77). Another systematic 
review and meta-analysis found that the odds ratio of having moderate/severe 
anxiety or depression are 6.30 and 3.25 in women with PCOS, respectively, after 
adjustment for BMI (73). Despite the well-documented evidence indicating that 
women with PCOS have a greater prevalence of anxiety symptoms, little is known 
about the underlying mechanisms and risk factors that could trigger these symp-
toms. A limited number of studies have investigated the correlation between the 
clinical/biochemical features of PCOS and anxiety symptoms and the outcomes 
are inconsistent. To start with, circulating testosterone and hirsutism, which are 
observed in the vast majority of women with the syndrome, have shown no or a 
weak positive correlation with anxiety symptoms in small-scale studies (73, 78, 79). 
Moreover, overweight and obesity, which are common features of PCOS, have 
been correlated with depression, but the correlation between BMI and  anxiety is 
unclear. Although many studies showed an association between PCOS and anxiety 
disorders, independently of BMI (79), there are a few studies showing correla-
tion between anxiety disorders and BMI in this population (80, 81). Last but not 
least, insulin resistance has not been associated to anxiety in women with PCOS 
(77). Overall, the most common features of PCOS do not seem to account for the 
increased rates of anxiety disorders in the affected women. 
An adverse intrauterine environment with androgen excess may lead to abnormal 
fetal development and has been evidenced to affect the brain function and behavior 
in the offspring later in life. In particular, increased fetal testosterone, measured 
in the amniotic fluid, was found to induce changes in the reward system of the 
assessed boys at the age of 10 (82). Moreover, children of women with PCOS, 
which are potentially exposed to higher levels of androgens during pregnancy, 
are at increased risk to develop autism spectrum disease and attention deficit 
hyperactivity disorder, with girls being more susceptible than boys (71, 83, 84). 
Moreover, in paper II of the current thesis, we showed that daughters of women 
with PCOS are also at increased risk for anxiety disorders. To explore whether 
these behavioral changes in the children of women with PCOS are due to environ-
9mental factors and/or genetic factors, Cesta et al. compared PCOS-exposed off-
spring to unrelated non-PCOS-exposed offspring and non-PCOS-exposed cousins 
(85). They found that PCOS-exposed offspring, especially girls, were at greater 
risk to develop attention-deficit/hyperactivity disorder, autism spectrum disorders, 
Tourette’s disorder and chronic tic disorders, compared to both unrelated offspring 
and cousins that were not exposed to maternal PCOS. These findings strengthen 
the hypothesis that maternal androgen excess can lead to behavioral changes in the 
offspring later in life, with or without genetic influences. Interestingly, the studies 
mentioned above show a stronger impact of maternal androgen excess on behavio-
ral changes in girls rather the boys. The factors that drive this sexually dimorphic 
response are not fully understood, but it is hypothesized that in utero androgen 
excess “masculinizes” the developing female brain by permanently reorganizing 
brain neural systems and leading to “hyper-masculine” behavioral traits that are 
found more often in boys than girls (e.g. attention-deficit/hyperactivity disorder 
and autism spectrum disorders) (86, 87). 
Studies in animal models have investigated how androgens affect brain function 
and behavior. In addition, the prenatally androgenized models of PCOS have been 
used to investigate the effects of in utero androgen excess in offspring brain func-
tion and behavior and tried to elucidate the involved mechanisms. Starting with the 
direct effects of chronic androgen exposure in female mice, it is shown that they 
develop anxiety-like behavior, an effect that is associated with increased mRNA 
expression of corticotropin releasing factor in the central nucleus of the amygdala 
(88). In addition, in a rat model of PCOS, continuous administration of dihydro-
testosterone led to anxiety-like behavior, which was accompanied by decreased 
basal morning and evening plasma corticosterone levels (89). With regard to the 
impact of in utero exposure to androgens, we and others have demonstrated that 
maternal androgen excess leads to anxiety-like behavior in the offspring, espe-
cially the female offspring (46, 47, 90, 91). Prenatal testosterone androgenization 
in female rats led to downregulation of androgen receptor, and upregulation of 
serotonergic and GABAergic genes in the amygdala (47), while another study found 
an increased hippocampal protein expression of brain-derived neurotrophic factor 
and decreased number of neuropeptide Y and parvalbumin immunoreactive cells 
(90). Using the prenatal dihydrotestosterone androgenized mouse model (study I 
in the thesis book), combined with maternal obesity and/or offspring obesity, we 
showed that female offspring exposed to maternal androgens had dysregulated 
gene expression of the adrenergic receptor 1 beta and the corticotrophin releasing 
hormone 2 in the amygdala, and dysregulated gene expression of the corticotropin-
releasing hormone and its receptors in the hypothalamus. A more detailed descrip-
tion and discussion of the results for paper I will follow in sections 2.4 and 2.5. 
Overall, clinical and pre-clinical studies strongly indicate that mental health dis-
orders in women with PCOS may originate during embryonic development due to 
androgen excess. Further research is needed to reveal the molecular mechanisms 
that are involved in this “programming”.
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2.2 Aims (Studies I and II)
The aims of the first two studies in the thesis were:
Study I: To investigate the distinct or combined effects of 1) in utero exposure to 
androgens, 2) maternal obesity, and 3) offspring obesity, on anxiety-like behavior 
in adult female and male mouse offspring; and to identify candidate genes that are 
implicated in anxiety-like behavior.
Study II: To investigate whether maternal PCOS increases the risk of anxiety 
disorders in daughters and sons, using a Swedish national register-based cohort 
study; to investigate whether maternal in utero exposure to androgens and/or 
maternal obesity leads to transgenerational transmission of anxiety-like behavior 
in adult female and male mice and to identify candidate genes that are involved 
in these behavioral changes. 
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2.3 Materials and Methods in studies I and II
2.3.1 Ethical considerations
All animal experiments in paper I and II were approved by the Stockholm Ethical 
Committee for Animal Research (Paper I: 121-16, Paper II: 10798-2017) in accord-
ance with the legal requirements of the European Community and the directive 
2010/63/EU of the European Parliament on the protection of animals used for 
scientific purposes. 
The register-based study in Paper II complies with the ethical standards of the 
relevant national and institutional committees on human experimentation and with 
the Helsinki Declaration of 1975, as revised in 2008. This study was approved by 
the regional ethical review board in Stockholm, Sweden (diary number 2013/862-
31/5; 2016/1214-32). The requirement for informed consent was waived because 
the study was register-based, and the included individuals were not identifiable 
at any time.
2.3.2 Swedish national register-based cohort study
The results in this study were generated from our collaborators Carolyn Cesta 
(Department of Medicine, Centre for Pharmacoepidemiology, Karolinska Institutet) 
and Mina Rosenqvist (Department of Medical Epidemiology and Biostatistics, 
Karolinska Institutet). A summary of the data sources and the analysis methods 
are presented in Table 3.
Table 3. Summary of the data sources and the analysis methods included in 
Paper II.
Population Data sources – Swedish 
Population Registers
Outcome Study Design 
and analysis 
method
All children born in 
Sweden from 1995 
to 2007 to mothers 
diagnosed with PCOS 
(n=12,955) and up to 
10 matched mothers 
without PCOS from 
the general population.
• Swedish Medical Birth 
Register 
• National Patient Register
• Prescribed Drug Register
• Total Population Register 
• Migration Register
• Cause of Death Register
Diagnoses of 
anxiety recorded 
in the children 
after age of 6. 
Matched Cohort 
Study
Stratified Cox 
regression  
models 
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2.3.3 Animal models and study designs
C57BL/6J mice were obtained from Janvier labs, were housed under a 12 h light–
dark cycle, with controlled conditions and had free access to water and food.
Paper I:
In order to generate prenatally androgenized mice combined with maternal obesity, 
12-week-old female mice were divided into two diet groups. The composition of 
the high-fat/high-sucrose (HFHS) diet was 17 kcal% protein, 43 kcal% carbo-
hydrate, and 40 kcal% fat, and together with the food pellets, mice had also free 
access to a 20% sucrose solution for drinking, supplemented with a vitamin mix of 
10 g/4000 kcal and a mineral mix of 35 g/4000 kcal. We chose to give this HFHS 
diet, in order to mimic the western diet that is characterized by high intake of fat 
and sugar. The composition of the control diet was 17 kcal% protein, 73 kcal% 
carbohydrate, and 10 kcal% fat.
To generate prenatally androgenized mice (PNA), we followed an established proto-
col that is widely used by researchers in the field (38, 39, 92). Using this model, we 
mimic the PCOS pregnancies with increased circulating androgen levels during the 
last trimester of pregnancies (31, 32). After 10 weeks on the diet, a female mouse 
on proestrus or estrus phase was placed with a male mouse in the afternoon and a 
plug the morning after mating was considered gestational day (GD) 0.5. On GD 
16.5 pregnant dams were injected in the interscapular area with 100 μl vehicle or 
250 μg DHT dissolved in a mixture of 5 μl benzyl benzoate and 95 μl sesame oil. 
To investigate how three environmental factors (maternal obesity, maternal andro-
gen excess and offspring obesity) interact with each other and affect anxiety-like 
behavior in the female and male offspring, we generated 16 groups of offspring:
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Paper II:
In Paper II we used the same PNA mouse model combined with maternal obesity, as 
in Paper I, with some refinements. Due to practical difficulties using the HFHS diet 
in Paper I, we used here a HFHS diet that combines high intake of fat and sucrose 
in the same food pellet, without the need of a sucrose bottle (93). The generation 
of PNA mice follows the same protocol as in Paper I. 
To investigate the transgenerational effects of maternal obesity and maternal 
androgen excess on anxiety-like behavior, we created three generations of mice. 
To investigate transgenerational epigenetic inheritance, we need to assess a gen-
eration that is not directly exposed to the environmental stimuli (94). In the case 
of maternal lineage (F0), both the developing first generation (F1) fetus and the 
primordial germ cells of second generation (F2) are directly exposed to the F0 
environmental stimuli. This transmission is referred as intergenerational epigenetic 
inheritance. The transgenerational epigenetic inheritance can be studied in the third 
generation that is not directly exposed. On the other hand, in the case of paternal 
lineage (F0), the transgenerational epigenetic inheritance can be studied in the F2 
generation of mice (Figure 2).
Figure 2. Illustration of intergenerational and transgenerational epigenetic inheritance of 
environmental stimuli in F0 maternal germline and F0 paternal germline. 
In paper II, we were also interested to investigate the transmission of anxiety-like 
behavior in the male germline. Therefore, we mated the F1 males and generated 
the second and third generation of male mice. 
The mating scheme and the groups that were studied are presented in Figure 3:
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Phenotype
HFHS
DHT
F1 male
F3 maleF2 male
mF2 male mF3 male
F1 female F2 female F3 female
Female germline
Male germline
Figure 3. Schematic illustration of experimental design. Prior to mating with male mice 
fed a control diet, F0 mothers were fed a control diet or a high fat-high sucrose (HFHS) diet 
for 6 weeks. During the embryonic days, E16.5-E18.5, pregnant mice were injected subcuta-
neously with dihydrotestosterone (DHT) or vehicle resulting in four lineages; CD+Vehicle 
(control); CD+DHT (androgenized); HFHS+Vehicle (obese); and HFHS+DHT (obese 
and androgenized). F1 female and F1 male offspring were mated with unrelated males 
and females fed CD, respectively, to generate F2 and thereafter to generate F3 offspring. 
Male germline refers to mF2 and mF3 male offspring from F1 males. F2 and F3 males are 
siblings to F2 and F3 female offspring (female germline).
2.3.4 Estrous cycle and anogenital distance
Mice are mammals and their female genital system is highly dynamic and influenced 
by hormones, similarly to human females. The histological appearance and function 
of the genital system is similar between the two species. Mice have an estrous cycle 
of 4-5 days, which is divided into 4 stages (proestrus, estrus, metestrus, diestrus), 
and corresponds to the human menstrual cycle. Disruption of estrous cycle in mice 
could reflect reproductive dysfunction. Here we used the vaginal cytology method 
to identify whether the mice have a normal estrous cycle or if they are acyclic. 
Three types of cells (nucleated epithelial cells, cornified epithelial cells, and leuko-
cytes) are identified in the estrous cycle, and the relative proportion of each cell 
type determines each estrous phase. The proestrus phase is characterized by the 
presence of nucleated and some cornified epithelial cells, followed by the estrus 
phase with predominantly cornified epithelial cells. The cycle continues with the 
metestrus phase, which consists of a mixture of three cell types and ends with the 
diestrus phase, where leukocytes is the predominant cell type (95). 
Women with PCOS and their daughters have longer anogenital distance (AGD) 
(96-98). AGD is evidenced to be a reliable newborn biomarker of in utero andro-
gen exposure. Therefore, in our studies, we measured the AGD in 3-week-old 
pups in order to confirm fetal androgen exposure.
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2.3.5 Assessment of anxiety-related behavior in mice
To assess anxiety-like behavior in the mice, we used two behavioral tests, the 
elevated plus maze and the open field. 
Elevated plus maze is a well-established behavioral assay that has been widely 
used for assessment of anxiety-like behaviors in rodents (99). The maze consists 
of four arms that form a plus shape, of which two are enclosed and two are open. 
This test assesses anxiety responses in rodents based on their preferences for dark, 
enclosed spaces and their fear of heights and open spaces. Rodents are placed at 
the center of the maze and their activity is recorded. Rodents that spend most of 
the time in the enclosed arms and avoid the open arms display anxiety. 
Open field is also a widely used behavioral test to assess anxiety in rodents (100). 
In most cases it is a square box with an empty large area that creates the feeling of 
openness. The test relies on the aversion of rodents for open and unknown environ-
ments. The box is divided into two parts, the center and periphery. Rodents are 
placed at the center of the open field and their activity is recorded. Rodents that 
tend to spend more time closer to the walls of the box and avoid exploring the 
center display higher anxiety. 
2.3.6 Gene expression analysis in the amygdala and 
hypothalamus
For papers I and II, we decided to follow a targeted approach, where we selected 
to assess several genes that have been previously implicated in anxiety. This 
approach can provide us with important information, yet it does not provide a com-
prehensive picture of whole genome expression. Real-time reverse transcription-
polymerase chain reaction (RT-PCR) using the TaqMan Gene Expression Assays 
was used to measure gene expression in the amygdala. RT-PCR was also used to 
assess the gene expression of corticotropin-releasing hormone and its receptors 
in the hypothalamus. 
2.3.7 Enzyme-linked immunosorbent assay (ELISA)
ELISA was used to measure the serum levels of testosterone and corticosterone in 
Paper I. This method detects and quantifies proteins in testing samples, by using 
antibodies that detect the protein of interest immobilized on the surface of a well. 
2.3.8 Statistical analysis
In the register-based cohort study, associations between maternal PCOS and off-
spring anxiety were estimated as hazard ratios with 95% confidence intervals using 
stratified Cox regression models with attained age as the underlying time scale. In 
addition to the maternal matching criteria, potential confounding variables were 
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adjusted for including offspring sex and year of birth, maternal age at child’s birth, 
maternal education, maternal region of birth, and maternal and paternal lifetime 
history of psychiatric disorders (adjusted Model). Robust standard errors were used 
to account for dependence between observations since several children from the 
same family were included in the study population. The analysis was conducted 
first for all offspring combined, and then stratified by offspring sex.
The statistical analyses in the mouse experiments were performed using the SPSS 
software in Paper I and SPSS software and GraphPad in Paper II. One-way or two-
way or three-way ANOVA were used to analyze our variables. Using two-way and 
three-way ANOVA, we were able to determine the main effects or the interactions 
of two or three independent variables, respectively. The detailed description of 
the statistical tests used in each experiment, can be found in the respective papers. 
The α level was set at P ≤ 0.05. 
2.4 Results of studies I and II 
2.4.1 Paper I: Maternal androgen excess and obesity induce 
sexually dimorphic anxiety-like behavior in the offspring
In utero exposure to androgens led to anxiety-like behavior in adult female, but 
not male offspring. On the other hand, maternal obesity increased anxiety-like 
behavior only in male offspring. The expression analysis of target genes involved 
in anxiety within amygdala and hypothalamus also showed a sexually dimorphic 
pattern. Female offspring exposed to DHT showed an upregulation of Adra1b 
and Crhr2 in the amygdala, and dysregulation of Crh and its receptors, Crhr1 and 
Crhr2, in the hypothalamus. Male offspring exposed to maternal obesity showed 
an upregulation of epigenetic markers in the amygdala and dysregulation of Crh, 
Crhr1 and Crhr2 in the hypothalamus, among other genes. While maternal diet 
did not lead to anxiety-like behavior in the female offspring, it did have an impact 
on gene expression in the amygdala of these mice. Finally, we showed that off-
spring diet did not have a direct impact on anxiety-like behavior in the offspring 
but led to dysregulated expression of many genes within the amygdala. This 
finding implies that offspring diet is an important environmental factor that acts 
synergistically with the maternal factors (maternal obesity and maternal andro-
gen excess) for the manifestation of the anxiety-like behavior in the offspring. A 
detailed description of the dysregulated genes in the amygdala and hypothalamus 
can be found in Tables 4-5:
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Table 5. Dysregulated genes in the hypothalamus of female and male offspring. 
Main or interaction effects of maternal androgen excess and maternal and offspring 
diet were calculated with 3-way ANOVA. *, indicates interaction effects.
Genes Females Males
Crh DHT exposure, Offspring diet Maternal*offspring diet
Crhr1 DHT exposure *maternal diet DHT exposure *maternal diet
Crhr2 DHT exposure DHT exposure *maternal diet
Table 4. Dysregulated genes in the amygdala of female and male offspring. Main or 
interaction effects of maternal androgen excess and maternal and offspring diet were 
calculated with 3-way ANOVA.*, indicates interaction effects.
Genes Females Males 
Neurotrophic factors and related receptors
Bdnf Maternal diet Maternal*offspring diet
Ntrk2 Maternal diet -
Ngfr - Maternal*offspring diet
Ntrk1 Maternal diet, Offspring diet -
Nrg1 DHT exposure*offspring diet, Maternal diet DHT exposure *offspring diet
Erbb4 Maternal diet Maternal diet
Genes involved in key neuronal networks
Gabbr1 Maternal diet Maternal*offspring diet
Htr2a Offspring diet -
Slc6a4 Maternal*offspring diet -
Nr3c1 Maternal*offspring diet -
Crhr2 DHT exposure*offspring diet Maternal diet
Adra1a - Maternal*offspring diet
Adra1b DHT exposure*maternal diet -
Grin2b Maternal diet -
Faah - Maternal*offspring diet
Ido2 - Maternal*offspring diet
Androgen and Estrogen receptors
Ar Maternal diet -
Gper1 Maternal diet Maternal*offspring diet
Ers1 DHT exposure*offspring diet, Maternal diet -
Metabolic genes
Sirt1 DHT exposure*offspring diet, Maternal diet Offspring diet
Insr DHT exposure*maternal diet Maternal*offspring diet
Irs1 - Maternal*offspring diet
Lepr Maternal diet
Il1r1 Maternal diet, Offspring diet Maternal diet
Histone mediators
Ep300 - Maternal diet, Offspring diet
Hdac1 - Maternal*offspring diet
Crebbp - Maternal*offspring diet
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2.4.2 Paper II: Prenatal androgen exposure causes a  sexually 
dimorphic transgenerational increase in offspring 
 susceptibility to anxiety disorders
Here we showed using a Swedish register-based cohort study that daughters of 
women with PCOS, but not sons, have a 78% increased risk of being diagnosed 
with anxiety compared to daughters of women without PCOS. We further explored 
whether maternal androgen excess and/or maternal obesity leads to anxiety-like 
behavior in male and female mice offspring and whether these two prominent 
environmental stimuli in the mother can lead to transgenerational transmission 
of anxiety-like behavior. We found, similarly to the human data, that only female 
offspring (F1) but not male offspring (F1), displayed an anxiety-like behavior 
due to maternal androgen excess with or without obesity in the first generation. 
Moreover, we showed that this anxiety-like behavior was transmitted into the third 
generation of female mice (F3), although no anxiety-like behavior was observed 
in the second generation (F2). No changes in anxiety-like behavior were observed 
in all three generations of male offspring following the female germline (F1-F3). 
Further, we investigated whether the male germline, here the first-generation 
male offspring (F1), transmit anxiety-like in the subsequent male generations. We 
found that only the third generation of male offspring (mF3) generated from the 
androgenized lineage and the obese lineage showed signs of anxiety-like behavior. 
These transgenerational behavioral changes were associated with gene expression 
changes within the amygdala. In the third generation of female offspring (F3), five 
genes (Camk2n1, Cacna2d1, Slc17a7, Btg2, and Dbh) were downregulated in the 
androgenized and in the obese lineages and three genes (Foxp2, Tial1, Adora2a) 
were upregulated only in the obese lineage. Lastly, the third generation of male 
offspring from the obese male lineage (mF3) had downregulated expression of 
the Btg2, Comt and Otx4.
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2.5 Conclusions
In Papers I and II, we observed a prominent sexually dimorphic behavioral response 
to an adverse intrauterine environment with androgen excess and obesity. While it 
is not feasible to study transgenerational transmission in humans – at least today – 
we observed in a mouse model of PCOS combined with maternal obesity that these 
adverse conditions can lead to behavioral changes in the first generation of female 
offspring and in the third generation of female offspring that was not directly exposed. 
These findings suggest a transgenerational epigenetic inheritance, which could be 
mediated through permanent changes in epigenetic mechanisms of somatic and germ 
cells. Another intriguing finding is the different behavioral response in males and 
females. Why do female offspring are more affected by maternal androgen excess 
than male offspring? It is believed that male fetuses can adjust testicular androgen 
production and prevent high levels of androgens prenatally. This hypothesis is 
 further supported by the finding that maternal testo sterone levels correlate with the 
testosterone levels of daughters but not sons (101). Further research is needed to 
increase our understanding of the mechanisms that lead to such sexual differences. 
Obesity is a common feature of PCOS, and we showed in the mouse studies that 
maternal obesity affects anxiety-like behavior in males more than in females. 
However, the gene expression analysis in the amygdala revealed changes due to 
maternal obesity in both sexes. Therefore, obesity is an important environ mental 
 factor that may reorganize brain neural systems in the offspring and lead to  behavioral 
changes later in life. 
In these studies, we followed a targeted approach to identify the involved genes that 
may mediate these behavioral changes. Although we did identify a dysregulation 
of numerous genes, there is need for a whole genome approach that will provide 
a deeper understanding of the involved pathways. Moreover, separate analysis 
of the amygdala nuclei could provide a more precise description of the involved 
mechanisms. 
Finally, these findings highlight the need for screening the children of women with 
PCOS for mental health disorders and underscore the detrimental effects of maternal 
obesity in offspring health. 
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3 PART 2: PCOS AND CARDIO-METABOLIC 
DISTURBANCES
3.1 Background 
3.1.1 Cardiovascular profile in PCOS
Cardiovascular diseases are the most common cause of death worldwide and they 
are related to dysfunction of the heart and blood vessels. A number of risk factors, 
such as obesity, hypertension, type 2 diabetes mellitus (T2DM) and abnormal lipid 
levels may increase the risk for cardiovascular diseases (102). 
Studies in women with PCOS have demonstrated that they are at an increased risk 
for cardiovascular diseases (103-107). Whether this increased risk is associated 
to the syndrome itself, or to the metabolic complications that are often present in 
women with the syndrome is unclear. Assessment of echocardiographic param-
eters have indicated structural alterations in young women with PCOS, including 
increased left ventricular mass and left atrial diameter (108, 109). Also, women 
with the syndrome are more prone to develop endothelial dysfunction, especially 
those who comorbid with insulin resistance and hyperandrogenemia (110, 111). 
Another study showed an increased intima-media thickness of common carotid and 
femoral arteries in women with the syndrome, which remained significant after 
adjustment for known risk factors (104, 112). In addition, women with PCOS were 
shown to have increased prevalence of coronary and aortic calcification, a finding 
that was associated with insulin resistance (113). On the other hand, another study 
did not show significant differences in coronary artery calcium or abdominal aortic 
plaque in women with PCOS (114). Increased levels of fibrinogen and plasminogen 
activator inhibitor 1 were also found in women with PCOS after adjustment for 
confounding factors, suggesting a prothrombotic state (115). Finally, hypertension 
is evidenced to be more prevalent among women with PCOS, a finding that was 
independent of age (116-119). 
Several studies have also investigated the impact of maternal PCOS on offspring 
cardiometabolic health. A recent study compared the cardiovascular and metabolic 
profile of young children of women with PCOS (2 groups: 3-4y and 7-8y) to a 
reference population (120). Their findings revealed that offspring from women 
with PCOS have a distinct cardiac and metabolic profile. Among the differences, 
they showed that the younger group had increased pulse pressure and left  ventricle 
internal diameter, yet the latter was within the normal range. The older group of 
children from women with PCOS had higher carotid intima-media thickness com-
pared to the reference group (120). In addition, another study showed that young 
adult daughters of women with PCOS, who had themselves a PCO morphology, 
displayed increased diastolic and mean arterial pressure (121). The clinical impor-
tance of these findings is not known and need further investigation. Yet, these 
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 findings suggest that maternal PCOS may predispose the offspring to cardiometa-
bolic complications, and the possible mechanisms of action await investigation.
Animal studies have tried to shed light into the link between PCOS and cardio-
vascular abnormalities. We and others have investigated the impact of androgens 
on cardiovascular system and how a hyperandrogenic maternal environment 
affect the cardiometabolic health of the offspring. A study investigating the impact 
of perinatal exposure to DHT in the offspring, showed vascular dysfunction in 
old mice (20-month-old) and this was associated with estrogen receptor β sup-
pression in endothelial progenitor cells early in life (122). Moreover, prenatally 
androgenized female rats exposed to testosterone in utero exhibited increased 
blood pressure in adulthood, and the authors suggested that androgens control 
the expression of protein kinase C δ (PKCδ) in the mesenteric arteries by increas-
ing PKCδ-mediated vasoconstriction and hypertension (123). Another study in a 
prenatally androgenized sheep model also found gene expression changes in the 
cardiac tissue and increased cardiomyocyte size after histological investigation 
(124). Our study (Paper III) further explored the mechanisms that contribute to 
the development of cardiovascular dysfunction in PCOS and the results will be 
discussed in detail in the section 3.4.1. 
3.1.2 Metabolic profile in PCOS 
Women with PCOS are more prone to become overweight or obese (25, 125). The 
prevalence of obese women with PCOS ranges between 50-80%, it is analogous to 
the prevalence of obesity in each country, and aggravates many features of PCOS, 
including hormonal, reproductive and metabolic parameters (3). A highly debated 
question is whether obesity per se could promote the development of PCOS. A 
recent study using a diet-induced obese rat model, showed that animals exposed to 
a chronic high-fat high-sucrose (HFHS) diet developed signs of PCOS, including 
polycystic ovaries and irregular estrous cycles (126). Moreover, studies in obese 
women with PCOS have shown that substantial weight loss improves some aspects 
of the syndrome (125, 127). Thus, while there is a clear link between PCOS and 
obesity, the exact interplay between them needs further investigation.
Several studies have reported impaired adipose tissue function in PCOS. To start 
with, enlarged adipocytes in the subcutaneous adipose tissue of women with PCOS 
have been found when compared with age and BMI paired matched controls (128). 
This adipocyte enlargement could indicate a dysfunctional lipolytic activity, which 
can promote fat accumulation in peripheral tissues and subsequently lead to insu-
lin resistance. A study in young non-obese women, showed a stark increase in 
the catecholamine-stimulated lipolysis of visceral fat cells of women with PCOS 
compared to controls, with no differences in adipocyte size. This increased lipo-
lytic rate was attributed to increased function of the protein kinase A-hormone 
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sensitive lipase complex (129). Moreover, larger adipocytes are associated with 
altered adipokine secretion, and women with PCOS have lower levels of circu-
lating adiponectin and increased levels of proinflammatory cytokines (128, 130). 
These findings have led to the hypothesis that a low-grade inflammation may be 
present in PCOS (131).
Insulin resistance is a central feature of PCOS, and studies have shown that 30-40% 
of women with the syndrome present with glucose intolerance and 10% of them 
develop T2DM by the 4th decade of their life (132-134). Moreover, another study 
showed that PCOS can lead to an earlier diagnosis of T2DM by 4 years (135). 
Obesity, especially visceral adiposity, is the best predictor of insulin resistance 
in PCOS and a recent review showed that increased BMI can augment a reduc-
tion of insulin sensitivity by 15% in PCOS compared to non-PCOS subjects (17, 
136, 137). Further, enlarged adipocytes together with low circulating adiponectin 
levels are two strong markers for insulin resistance in women with PCOS (128).
3.1.3 Sympathetic activity and PCOS
The most common features of PCOS, including hyperandrogenemia, hyper-
insulinemia, obesity and cardiovascular diseases, have all been associated with 
an increased sympathetic nerve activity (138). Women with PCOS have enhanced 
sympathetic nerve activity, as indicated by direct muscle sympathetic nerve  activity 
recordings and decreased vagal activity (23, 24, 139, 140). In addition, other stud-
ies in women with the syndrome, revealed an increased catecholaminergic density 
of nerve fibers in the ovaries (141), increased levels of dopamine and norepin-
ephrine in the follicular fluid and alterations in noradrenaline deamination (142, 
143). These findings indicate changes in the sympathetic tone of these women. 
Animal studies have shown that an increase of ovarian nerve growth factor levels 
precedes the development of PCOS-like features (144, 145). Another study that 
investigated the role of peripheral noradrenergic neurons in the development of 
the syndrome, found that elimination of these neurons by pharmacological proce-
dures prevents ovulatory dysfunction and hyperandrogenism in a mouse model of 
PCOS. Moreover, in the same study they demonstrated that sympathetic denervation 
can restore ovulation, but not hyperandrogenism (146). Other studies have showed 
an altered catecholamine content in the ovaries of a PCOS-like mouse model, 
with increased levels of noradrenaline and down-regulation of β-adrenoreceptors 
(147-149). Overall, these data suggest that sympathetic hyperactivity may play 
an important role in the ovarian dysfunction in PCOS and provide support for a 
neural involvement in the pathophysiology of PCOS
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3.1.4 Nerve growth factor (NGF) and PCOS
NGF is a neurotrophic factor that was discovered in the early fifties and since then 
numerous studies have revealed its involvement in a broad spectrum of biologi-
cal activities (150). NGF can act in both neuronal and nonneuronal cells and it is 
evidenced to be an important mediator of crosstalk between systems that control 
homeostatic functions (151). To name a few functions, NGF is critical for the 
development and maintenance of the peripheral sympathetic and some sensory 
neurons, it is involved in immune cell function, endocrine function and behavioral 
responses. Within the ovary, it plays a role in follicle maturation and ovulation 
(152), as indicated by studies in the ovaries of rodent (153, 154), goat (155, 156) 
and sheep models (157). In addition, it contributes to the production of steroids in 
the ovary, as observed in rodents (158), cows (159) and humans (160). 
A lack or excess of NGF in target sites may initiate perturbations. Looking into 
the adverse effects of NGF imbalance within the ovary, rodent studies have shown 
that lack of NGF impairs the early follicular development (161) and causes infer-
tility (162). An excess of ovarian NGF in transgenic mice (17NF mice) causes 
increased ovarian sympathetic tone, irregular cyclicity, impaired fertility, enhanced 
ovarian sex steroid production and increased granulosa cell apoptosis (62, 163). 
Interestingly, it has been shown that women with PCOS have increased levels of 
NGF in the follicular fluid and their granulosa cells produce more NGF compared 
to women without the syndrome (62, 164). 
These findings on the role of NGF in ovarian function, led us to further investigate 
the 17NF transgenic mouse model with overproduction of ovarian NGF, with goal 
to elucidate the possible crosstalk between ovarian disruption and the other com-
plications that are present in women with PCOS. These data are part of Paper IV 
and will be described in detail in the following sections. 
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3.2 Aims (Studies III and IV)
The aims of the study III and IV in the thesis were:
Study III: To investigate the effects of maternal androgen excess with or without 
maternal obesity on the metabolic and cardiac profile of female offspring. Also, to 
investigate the impact of continuous dihydrotestosterone exposure on the cardio-
vascular system using a mouse model of PCOS. 
Study IV: To investigate the effects of ovarian nerve growth factor excess on 
embryonic development, as well as on reproductive and metabolic function in 
adult life, using a transgenic mouse model that resembles PCOS-like features. 
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3.3 Materials and Methods in papers III and IV 
3.3.1 Ethical considerations in papers III and IV
All animal experiments in paper III and IV were approved by the Stockholm 
Ethical Committee for Animal Research (Paper III: 10798-2017, Paper IV: 865-
2019) in accordance with the legal requirements of the European Community and 
the directive 2010/63/EU of the European Parliament on the protection of animals 
used for scientific purposes.
3.3.2 Animal models and study design in paper III
In Paper III, we used two mouse models of PCOS. The first one is the PNA mouse 
model refined with maternal obesity and was generated exactly as the PNA mouse 
model in paper I. In paper III we followed only the female offspring that were 
fed with a control diet. Moreover, we studied in a separate batch of PNA mice, 
the effects of maternal androgen exposure on the hearts of newly born female 
pups (postnatal day 1). Finally, to study the effects of dihydrotestosterone on the 
cardio vascular profile in a PCOS context, we used a mouse model of PCOS that is 
generated by continuous exposure to dihydrotestosterone from adolescence. This 
is an established mouse model of PCOS and is known to develop reproductive and 
metabolic complications within 90 days of dihydrotestosterone exposure (53). In 
brief, 4-week-old female mice received an implant containing  dihydrotestosterone, 
or blank, or dihydrotestosterone+flutamide (androgen receptor blocker). In our 
study, mice were exposed for 7 weeks, as we wanted to assess cardiac function, 
without the possible confounding effects of disturbed glucose metabolism on car-
diac function. Flutamide is a synthetic nonsteroidal drug that binds to the androgen 
receptor and prevents androgens, including dihydrotestosterone, to bind to the 
same receptors. In women with PCOS, flutamide is used to treat hirsutism (165). 
Here, it was used to investigate whether it can prevent the possible adverse effects 
of dihydrotestosterone on the cardiovascular system. 
3.3.3 Methods used in Paper III
3.3.3.1 Reproductive and Metabolic assessment
The reproductive function was assessed with the estrous cyclicity assessment as 
described in the first part (Study I). We assessed body composition using dual-
emission X ray absorptiometry (DEXA) in the PNA mice and echoMRI in the 
DHT-implanted mice. Both tests provide accurate data regarding the lean mass and 
fat mass of the testing animals. DEXA method requires the anesthesia of the test-
ing animal, which is not optimal, while echoMRI is quicker and can be performed 
in non-anesthetized animals. Therefore, once we received access to an echoMRI, 
we chose this method for testing. Moreover, we assessed glucose metabolism in 
the testing mice with an oral glucose tolerance test and an insulin tolerance test. 
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3.3.3.2 Cardiovascular assessment
Blood pressure was assessed in the PNA mice by using the Coda High Throughput 
Non-invasive Tail Monitoring System. The tail cuff method is non-invasive, and it 
is widely used for blood pressure measurement is rodents. However, it is not the 
gold standard for continuous blood pressure and heart rate recordings in awake 
animals, as it lacks high sensitivity. Radio telemetry is a more sensitive method 
for blood pressure measurement, but it requires surgery and implantation of trans-
mitters in the abdomen or subcutaneously, which could potentially influence the 
results in our model of PCOS. 
Mice were subjected to transthoracic echocardiography for cardiac function assess-
ment. This test provides information about functional and structural changes in 
the heart and in our studies, it was performed by expertized personnel. We also 
measured the cardiomyocyte size by histological examination. Histology provides 
additional information about the structure of the tissue and identifies possible 
changes at the level of the cell – here the cardiomyocyte. 
Finally, we assessed vascular function using wire myography. Myography is a 
technique used to assess functional responses and vascular reactivity of small 
resistance arteries. Here, mesenteries arteries were mounted in a myograph and 
after normalization, their contractile and vasodilator properties were assessed. 
3.3.3.3 NADPH oxidase activity in the left ventricle of the heart
NADPH oxidase, a transmembrane enzyme complex, drives the production of 
reactive oxygen species. Therefore, the activity of NADPH oxidase is critical for 
the production and availability of reactive oxygen species in our body. A dysregu-
lation of NADPH oxidase activity is evidenced to play an important role in the 
onset of cardiovascular complications (166), so we measured its activity in the 
left ventricle of the heart in our PNA mice. 
3.3.3.4 Gene expression analysis in the left ventricle of the heart
The expression of several genes with known implications in cardiac hyper trophy, 
fibrosis, calcium signaling, redox signaling and androgen-related genes was 
 measured with RT-PCR. 
3.3.4 Animal model and study design in paper IV
In paper IV, we used a transgenic mouse model of PCOS that overexpresses nerve 
growth factor selectively in the theca-interstitial cells of the ovary and they are 
termed 17NF. The 17NF mice were generated at the Oregon Health and Science 
University Transgenic/Gene Targeting Core, USA, by pronuclear microinjection 
of the transgene construct into fertilized eggs obtained from B6D2F1/J mice 
 followed by transfer of the injected eggs into the uterus of a surrogate mother. The 
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transgene DNA construct is as follows: “The promoter sequence (17α-OH) was 
derived from the mouse gene [S41708], the source of the insulin II intron A was rat 
[J00748], the NGF minigene was human [V01511], and the GH polyadenylation 
signal was from rat [V01239]. All components except the promoter were part of a 
cassette known to express NGF” (62). The 17NF mice were bred to homozygosity. 
They were kindly provided to us by Dr. Cecilia Garcia-Rudaz, Monash University, 
Australia and were rederived at Comparative Medicine, Karolinska Institutet before 
experimental use. We used various batches of the homozygous 17NF mice for the 
developmental, reproductive and metabolic assessments, and we confirmed the 
transgene expression in each of them by genotyping. In all experiments, mice of 
B6D2F1 background were used as controls. Finally, mice were housed under a 
12 h light–dark cycle, with controlled conditions and had free access to water and 
in-house chow food. 
3.3.5 Methods used in Paper IV
3.3.5.1 Embryonic assessment
To investigate the impact of ovarian overexpression of NGF on fetal development, 
control and transgenic mice were mated and the embryonic development on ges-
tational days 12.5 (GD12.5) and 18.5 (GD18.5) was assessed. We chose these two 
critical timepoints, as on GD12.5 the gonad differentiation has been completed 
and on GD18.5 the gestational period is almost complete (expected delivery from 
day 19). To evaluate the development of the fetuses, the crown to rump length 
and gonad size were measured. Proper function of the placenta is critical for the 
development of the embryo; therefore, we also assessed the placental morphology 
and target genes that regulate fetal growth and placental function. 
3.3.5.2 Reproductive assessment
The 17NF mice have compromised reproductive activity (62). To further inves-
tigate this finding and assess whether it has embryonic origins, we measured the 
number of germ cells in the developing fetuses on GD12.5 and GD18.5. Germ cells 
were immunostained and distinguished by mouse vasa homologue or E-cadherin 
staining. Moreover, primary oocyte maturation was assessed by immunostaining 
in GD18.5 ovaries. 
In 3-week-old pups, anogenital distance was measured as an indicator of in 
utero androgen exposure, and the estrous cyclicity was assessed in adult mice, as 
described in Part I (Paper I). 
3.3.5.3 Metabolic assessment 
In vivo testing: The body weight development was followed from adolescence to 
adulthood. In adult mice, body fat and lean mass were measured by echoMRI, and 
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glucose metabolism was assessed by an oral glucose tolerance test and an insulin 
tolerance test. Moreover, mice were placed in metabolic cages to assess energy 
metabolism by indirect calorimetry. 
In vitro and ex vivo testing: In addition to the in vivo testing of glucose metabolism, 
we also investigated the glucose uptake in target tissues using 14C radiolabeled glu-
cose (D-[14C(U)]-Glucose- tracer). This glucose uptake assay allows the measure 
of glucose uptake and glucose transport (incorporation into lipids). 
We isolated adipose precursor cells from the stromal vascular fraction of sub-
cutaneous fat depots from 6-week-old mice. Adipose precursor cells were then 
differentiated to mature adipocytes, and expression of key genes involved in the 
differentiation process were assessed during three timepoints. The first timepoint 
was the start of the differentiation process, followed by the 6th day of the differen-
tiation in which preadipocytes have been formed and completed by the 12th day, 
in which mature adipose cells have been formed. 
Ex-vivo lipolytic rate was measured in subcutaneous and parametrial fat explants 
from adult mice. Here we measured both basal lipolysis (no stimulation) and 
stimulated lipolysis (stimulation with forskolin). Also, morphological assessment 
of these two white fat explants was performed by histological examination.
Changes in the lipolytic activity in the fat tissue can lead to increased free fatty 
acid release into the circulation and to increased triglyceride content in the liver. 
Therefore, we measured the triglyceride and non-esterified fatty levels in the serum, 
and triglyceride deposition in the liver by in vitro enzymatic colorimetric methods.
3.3.5.4 Plasma catecholamines
Plasma catecholamine levels were determined with a validated high-pressure liquid 
chromatography – electrochemical detection (HPLC-EC) system.
3.3.5.5 Gene expression in target tissues
The expression of target genes in the embryonic ovaries, adult ovaries, placenta, 
white adipose tissue and liver were analyzed by RT-PCR. 
3.3.6 Statistical analysis in Papers III and IV
The statistical analyses were performed using the SPSS software in Paper III and the 
SPSS software and GraphPad in Paper IV. One-way ANOVA or two-way ANOVA 
or Student’s t-test was used in Paper I, and Student’s t-test was used in Paper IV 
in normalized data. The detailed description of the statistical tests used in each 
experiment, can be found in the respective papers. The α level was set at P ≤ 0.05
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3.4 Results of studies III and IV
3.4.1 Paper III: Maternal androgen excess induces cardiac 
hypertrophy and left ventricular dysfunction in female 
mice offspring
Here we showed that maternal androgen excess, with or without maternal obe-
sity, leads to cardiac hypertrophy in the adult female offspring, as indicated by 
increased interventricular septal and posterior wall thickness. These structural 
cardiac changes were accompanied by expression changes of genes involved in 
pathological cardiac hypertrophy (Nppb, Trim63), fibrosis (Tgfbeta1, Col1a1), 
calcium signaling (Ryr2, Atp2a2), redox signaling (Sod2) and steroid metabo-
lism (Srd5a2, Srd5a3). These cardiac changes were not associated to metabolic 
dysfunction or changes in blood pressure in the adult mice. We investigated the 
neonatal female pups for early cardiac changes, which could account for the 
long-lasting effects observed in adulthood. Interestingly, we found that the left 
ventricle from neonatal PNA mice had upregulated expression of genes involved 
in cardiac hypertrophic remodeling (Mef2c), calcium signaling (Slc8a2), and the 
androgen-related gene, Odc1, along with downregulation of the Nox4 gene that 
is involved in redox signaling. These findings indicate that the cardiac changes 
in adult mice are a result of early cardiac remodeling due to in utero exposure 
to androgens. Further, by using another mouse model of PCOS with continuous 
exposure to androgens from adolescence to adulthood, we showed that continuous 
exposure to androgens leads to cardiac hypertrophy, similarly to the PNA model. 
Moreover, these mice had impaired vascular function, as indicated by increased 
contractile responses of the mesenteric arteries. Treatment with the antiandrogen 
flutamide partially alleviated these effects. 
3.4.2 Paper IV: Excess of ovarian nerve growth factor impairs 
embryonic development and causes reproductive and 
metabolic dysfunction in adult mice
In this study we used a transgenic mouse model of PCOS (17NF mice), and we 
showed that ovarian NGF excess can lead to adverse fetal development and to 
reproductive and metabolic dysfunction in adult life. Starting with the embryonic 
assessment, we found that the 17NF female mice were growth-restricted, partly due 
to placenta dysfunction. Moreover, we showed that they had a reduced number of 
germ cells and delayed gonocyte and primary oocyte maturation. In adult life, they 
displayed disrupted estrous cyclicity accompanied by ovarian expression changes 
of steroidogenic genes and epigenetic markers. The adult 17NF mice had higher 
circulating levels of dopamine. Assessment of their metabolic profile revealed an 
increased fat mass, impaired glucose tolerance and lower energy expenditure. In 
addition, we found a larger volume of the subcutaneous fat depot with enlarged 
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adipocyte size in the 17NF mice, accompanied by dysregulated gene expression 
(Ppardelta, Zfp423, Cebpbeta, and Fasn), and an enhanced preadipocyte differ-
entiation. In the parametrial fat of the 17NF, we demonstrated a heterogeneous 
distribution of adipocytes with a mixture of smaller, immature cells and larger 
mature adipocytes, and dysregulated expression of genes involved in adipogenesis 
(Ppargamma), glucose metabolism (Slc2a4), catecholamine metabolism (Adrb3, 
Comt, Maoa), fibrosis (Col6a1, Col6a3) and inflammation (Tnf). The 17NF mice 
also developed liver steatosis. Finally, we showed an increased glucose uptake in 
the ovary and brown adipose tissue, and reduced glucose uptake in the extensor 
digitorum longus muscle. 
3.5 Conclusions
In this part of the thesis, I described the cardiovascular and metabolic complica-
tions that are often present in women with PCOS. The developmental origins of 
these complications were investigated by using three different mouse models of 
PCOS. In both studies we focused on the effects of an adverse maternal and/or 
postnatal environment on female health. In paper III, by using the PNA model, 
we demonstrated an early cardiac remodeling that led to cardiac hypertrophy in 
adulthood without the presence of other metabolic complications. We also showed 
that postnatal exposure to androgens led to cardiac hypertrophy and increased 
vasocontractile responses. In paper IV, by using the transgenic 17NF mice, we 
demonstrated that excess of ovarian NGF accompanied by ovarian sympathetic 
hyperactivity, can initiate disturbances in the developing fetus and further contribute 
to reproductive and metabolic dysfunction in adult life, affecting multiple organs. 
The cardiac profile of the 17NF mice warrants future investigation. 
Our findings highlight the complexity of the syndrome and pinpoint that differ-
ent stimuli can initiate the PCOS-associated symptoms, at least in our preclinical 
models. To identify the origins of these stimuli, the maternal androgen excess 
(Paper III) and ovarian NGF excess (Paper IV), was out of the scope of these 
studies, but they are fundamental questions to be answered. To date, there are no 
naturally occurring animal models of PCOS, with the exemption of a study that 
identified hyperandrogenic rhesus monkeys that developed PCOS-related traits 
(167). The animal models of PCOS that we are currently using provide valuable 
information about the order of the events that take place and how common fea-
tures of the syndrome affect the manifestation of others, but they cannot identify 
the genesis of PCOS.
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4 THIS THESIS AND FUTURE DIRECTIONS
It is becoming evident from the current work that PCOS is a complex syndrome, 
which affects multiple organs and may have strong environmental and epigenetic 
influences, in addition to its multigenic character. 
Here, we focused on the environmental factors that can contribute to the onset 
of the syndrome. We and others have provided adequate evidence to support that 
maternal androgen excess can initiate PCOS-like features in the offspring for sev-
eral generations, i.e. transgenerational transmission. Future studies may focus on 
the molecular mechanisms that govern these phenotypic manifestations. Moreover, 
due to the multi-organ involvement, studies using advanced methods that allow 
the study of multi-organ communication would provide novel knowledge about 
the interaction between target organs and would possibly help to identify common 
affected pathways with ultimate goal the development of more effective treatments 
for women with the syndrome. This approach could be implemented using even 
human material (e.g. cells) to provide direct translational outcomes. 
Future considerations for the studies in the current thesis:
Studies I and II: The evident sexually dimorphic behavior in both the animal and 
the human studies points towards the need to study further the involved mecha-
nisms. Some mental health disorders are more prevalent in females, while others 
in males. The exact mechanisms of action are not clear. A better understanding of 
the sex steroid effects in the male and female brain neural systems could help to 
the development of sex-oriented treatments for more effective drug responses. In 
this section, we also demonstrated that the anxiety-like behavior can be transmit-
ted transgenerationally. The epigenetic mechanisms that drive this transmission 
are unknown and need to be studied. 
Last, but not least, a few register-based studies indicate that mental health dis-
orders in the offspring of women with PCOS may be both due to maternal andro-
gen excess and genetic predisposition. Both factors are important, and it is critical 
to identify the genes that may drive the increased risk for mental disorders, and 
whether these genes are shared between PCOS and specific mental disorders. 
Regarding maternal androgen excess, pharmacological and/or lifestyle interven-
tions aiming to improve androgen levels in these women could bring substantial 
benefits to their children and future studies should assess the effects of different 
maternal treatment options on offspring health. 
Studies III and IV: The results of study III concerning the cardiovascular risk in 
women with the syndrome and their daughters need further investigation. Despite 
the increasing number of studies showing adverse cardiac manifestations in both 
populations, little is known about the clinical importance of these data, and whether 
they can lead to an increased risk of mortality later in life. A limited number of 
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studies have assessed the mortality rates in these women and the results indicate a 
similar prevalence of adverse cardiovascular events, despite the increased cardio-
vascular risk factors in women with PCOS (168-170). Therefore, studies including 
a larger sample size and broader age ranges would provide a more complete picture. 
Flutamide was used in study III to prevent the possible adverse effects of andro-
gens on the cardiovascular system. In our study, it did not effectively alleviate the 
increased vasoconstriction after androgen exposure. Considering the results of our 
study, future studies should investigate the efficacy of various doses of flutamide 
treatment on the cardiovascular system and compare flutamide to other anti- 
androgenic compounds that reduce the 5a-reductase activity, such as finasteride. 
Both flutamide and finasteride have been used as a treatment to the androgen-
related symptoms (e.g. hirsutism) in women with PCOS (165). 
Study IV provided indication that overexpression of ovarian NGF, accompanied 
by an increase in ovarian sympathetic activity, can initiate many of the symptoms 
observed in women with PCOS. Women with PCOS often deliver babies small or 
large for gestational weight (171, 172). Whether this is an outcome of changes in 
sympathetic nerve activity needs further research. We also observed reproductive 
and metabolic dysfunction in adult mice. These findings recapitulate many aspects 
of the human PCOS condition. Despite the fact that we provided an extensive 
picture of the adverse effects that take place in these mice, the exact sequence of 
events is not known. Moreover, in future studies it would be interesting to inves-
tigate the sympathetic nerve activity in daughters of women with the syndrome, 
and the possible association between changes in sympathetic nerve activity and 
adverse phenotypic manifestations. Finally, studies modulating sympathetic nerve 
activity in women with PCOS could provide important insight into the possible 
effects on the PCOS-symptoms.
Graphical summary of this thesis:
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